21. The method of claim **20**, wherein the phosphate of β-D-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane is administered in a form that is at least 95% free of its corresponding β-L-enantiomer.

22. The method of claim **20**, wherein the phosphate of β-D-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane is administered as an isolated enantiomer.

* * * * *